Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.09.2017 | review

Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology

verfasst von: Assoc. Prof. Lyubomir A. Dourmishev, MD, PhD, Dimitrina V. Guleva, MD, Prof. Ljubka G. Miteva, MD, PhD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 9-10/2018

Einloggen, um Zugang zu erhalten

Summary

Background

Connective tissue diseases are a heterogeneous group of autoimmune disorders affecting not only skin, but also various organs and systems. First-line treatment of connective tissue diseases is systemic steroids as monotherapy or combined with immunosuppressive drugs. Since intravenous immunoglobulins (IVIGs) have been found to be effective for various autoimmune dermatoses, their indications have expanded tremendously.

Objective

The aim this review article is to highlight the indications, effectiveness, and side effects of high doses immunoglobulins for treatment of patients with connective tissue diseases.

Methods

MEDLINE was searched for prospective clinical studies and case reports on IVIG treatment of lupus erythematosus, dermatomyositis, systemic sclerosis, and mixed connective tissue disease (MCTD). Included studies were analyzed and discussed in terms of the different disease entities.

Results and conclusion

IVIGs are a valuable alternative for treating therapy-resistant patients with lupus erythematosus, dermatomyositis, systemic sclerosis, or MCTD. However, more placebo-controlled clinical studies are needed to evaluate the exact indications and therapeutic regimens.
Nächster Artikel Histopathologic pitfalls of Mohs micrographic surgery and a review of tumor histology
Literatur
1.
Bruton OC. Agammaglobulinemia. Pediatrics. 1952;16:722–8.
2.
Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–31.CrossRefPubMed
3.
Cherin P, Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs. 2010;24:211–23.CrossRefPubMed
4.
Baleva M, Nikolov K. The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis. Int J Rheumatol. 2011;2011:829751.CrossRefPubMedPubMedCentral
5.
Nikolov K, Nikolova-Vlahova M, Baleva M. Side effects of intravenous immunoglobulins (IVIG). In: Allegro R, editor. Plasmopheresis and Immunoglobulins. New York: Nova; 2014. pp. 191–204.
6.
Negi VS, Elluru S, Siberil S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27(3):233–45.CrossRefPubMed
7.
Zhou C, Huang M, Xie L, et al. IVIG inhibits TNF-α-induced MMP9 expression and activity in monocytes by suppressing NF-κB and P38 MAPK activation. Int J Clin Exp Pathol. 2015;8(12):15879–86.PubMedPubMedCentral
8.
Kuhn A, Sticherling M, Bonsmann G. Clinical manifestations of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2007;5(12):1124–37.CrossRefPubMed
9.
Corvetta A, Della Bitta R, Gabrielli A, et al. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheumatol. 1989;7(3):295–9.PubMed
10.
Boletis JN, Ioannidis JP, Boki KA, et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999;354:569–70.CrossRefPubMed
11.
Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum. 2000;29:321–7.CrossRefPubMed
12.
Costa N, Pires AE, Gabriel AM, et al. Broadened T‑cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T‑cells. J Clin Immunol. 2013;33(2):349–60.CrossRefPubMed
13.
Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat. 2004;15(1):46–50.CrossRefPubMed
14.
Piette JC, Frances C, Roy S, et al. High-dose immunoglobulins in the treatment of refractory kg/day for five consecutive days each month for a 12-cutaneous lupus erythematosus: open trial in 5 patients. Arthritis Rheum. 1995;38(Suppl 9):304.
15.
Espírito Santo J, Gomes MF, Gomes MJ, et al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol. 2010;38(2–3):307–18.CrossRefPubMed
16.
Lampropoulos CE, Hughes GR. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol. 2007;26:981–3.CrossRefPubMed
17.
Généreau T, Chosidow O, Danel C, et al. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol. 1999;135(9):1124–5.CrossRefPubMed
18.
Kreuter A, Hyun J, Altmeyer P, et al. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2005;85(6):545–7.PubMed
19.
Brasileiro A, Fonseca Oliveira J, Pinheiro S, et al. Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin. Lupus. 2016;25(6):663–5.CrossRefPubMed
20.
Ky C, Swasdibutra B, Khademi S, et al. Efficacy of intravenous immunoglobulin Monotherapy in patients with cutaneous lupus Erythematosus: results of proof-of-concept study. Dermatol Reports. 2015;7(1):5804.CrossRefPubMedPubMedCentral
21.
De Pità O, Bellucci AM, Ruffelli M, et al. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus. 1997;6(4):415–7.CrossRefPubMed
22.
Cieza-Díaz DE, Avilés-Izquierdo JA, Ceballos-Rodríguez C, et al. Refractory subacute cutaneous lupus erythematosus treated with rituximab. Actas Dermosifiliogr. 2012;103(6):555–7.CrossRefPubMed
23.
Wollina U, Looks A, Kammler H‑J. Intravenous immunoglobulin therapy in dermatology: overview and center experience. An Bras Dermatol. 1998;73(3):255–9.
24.
Dourmishev LA, Dourmishev AL, Schwartz RA. Dermatomyositis: cutaneous manifestations of its variants. Int J Dermatol. 2002;41(10):625–30.CrossRefPubMed
25.
26.
Tansley S, Shaddick G, Christopher-Stine L, et al. Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. Clin Exp Rheumatol. 2016;34(5):880–4.PubMed
27.
Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729–35.CrossRefPubMedPubMedCentral
28.
Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.CrossRefPubMed
29.
Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol. 1999;26(7):457–9.CrossRefPubMed
30.
Shahani L. Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin. BMJ Case Rep. 2012;18:2012.
31.
Amano H, Nagai Y, Katada K, et al. Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin. Br J Dermatol. 2007;156:1390–2.CrossRefPubMed
32.
Imataka G, Arisaka O. Long-term, high-dose intravenous immunoglobulin therapy in a patient with banker-type juvenile dermatomyositis. Cell Biochem Biophys. 2014;69(3):747–8.CrossRefPubMedPubMedCentral
33.
Speth F, Haas J‑P, Hinze CH. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. Pediatr Rheumatol Online J. 2016;14(1):52.CrossRefPubMedPubMedCentral
34.
Cafardi JM, Sami N. Intravenous immune globulin in Amyopathic Dermatomyositis – report of two cases and review of the literature. Open Rheumatol J. 2015;9:77–81.CrossRefPubMedPubMedCentral
35.
Wollina U, Looks A, Schneider R, et al. Disabling morphoea of childhood-beneficial effect of intravenous immunoglobulin therapy. Clin Exp Dermatol. 1998;23(6):292–3.CrossRefPubMed
36.
Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 2004;50(3):1005–7.CrossRefPubMed
37.
Asano Y, Ihn H, Asashima N, et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford). 2005;44(6):824–6.CrossRef
38.
Ihn H, Mimura Y, Yazawa N, et al. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol. 2007;156(5):1058–60.CrossRefPubMed
39.
Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31(2 Suppl 76):151–6.PubMed
40.
Szekanecz Z, Aleksza M, Antal-Szalmás P, et al. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects. Clin Rheumatol. 2009;28(3):347–50.CrossRefPubMed
41.
Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148–59.CrossRefPubMed
42.
Bodemer C, Teillac D, Le Bourgeois M, et al. Efficacy of intravenous immunoglobulins in sclerodermatomyositis. Br J Dermatol. 1990;123(4):545–6.CrossRefPubMed
43.
Ulmer A, Kötter I, Pfaff A, et al. Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. J Am Acad Dermatol. 2002;46(1):123–7.CrossRefPubMed
44.
Matsuda M, Miki J, Oguchi K, et al. Fasciitis in mixed connective tissue disease successfully treated with high-dose intravenous immunoglobulin. Intern Med. 2003;42(9):910–1.CrossRefPubMed
45.
46.
Palabrica FR, Kwong SL, Padua FR. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac Allergy. 2013;3(4):249–56.CrossRefPubMedPubMedCentral
47.
Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87:206–18.PubMed
48.
Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223–6.CrossRefPubMed
49.
Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259–62.CrossRefPubMed
50.
Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med. 1986;314:560–4.CrossRefPubMed
51.
Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. Adverse reactions of prophylactic intravenous immunoglobulin; A 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009;19(2):139–45.PubMed
52.
Krug P, Boyer O, Balzamo E, et al. Nephrotic syndrome in Kawasaki disease: a report of three cases. Pediatr Nephrol. 2012;27(9):1547–50.CrossRefPubMed
53.
Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve. 1997;20:1102–7.CrossRefPubMed
54.
Vecchietti G, Kerl K, Prins C, et al. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol. 2006;142(2):213–7.CrossRefPubMed
55.
Kurata M, Horie C, Kano Y, et al. Pompholyx as a clinical manifestation suggesting increased serum IgG levels in a patient with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Br J Dermatol. 2016;174(3):681–3.CrossRefPubMed
56.
Blackhouse G, Gaebel K, Xie F, et al. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc. 2010;8:14.CrossRefPubMedPubMedCentral
57.
Bamrungsawad N, Chaiyakunapruk N, Upakdee N, et al. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand. Pharmacoeconomics. 2015;33(5):521–31.CrossRefPubMed
Metadaten
Titel
Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology
verfasst von
Assoc. Prof. Lyubomir A. Dourmishev, MD, PhD
Dimitrina V. Guleva, MD
Prof. Ljubka G. Miteva, MD, PhD
Publikationsdatum
01.09.2017
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 9-10/2018
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-017-0595-x

Weitere Artikel der Ausgabe 9-10/2018

Cutaneous Langerhans cell histiocytosis

  • brief report

Palmar hyperhidrosis treated by noninvasive ultrasound stellate ganglion block

  • case report

Dog bite injury — alar repair with composite graft

  • case report

Mosaic capillaroscopic findings in systemic sclerosis

  • case report

Psychosocial aspects associated with use of sunscreen, natural sunlight exposure, and artificial tanning

  • original article

Indikationen und Kontraindikationen der modernen Kompressionstherapie

  • übersicht